3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
5
Gastrointestinal
4
Thoracic
2
Breast
2
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
5744
Lung Neoplasms
3716
Small Cell Lung Carcinoma
1017
Breast Neoplasms
667
Neoplasms
616
Colorectal Neoplasms
556
Melanoma
479
Ovarian Neoplasms
434
Neoplasm Metastasis
431
Pancreatic Neoplasms
386
Stomach Neoplasms
332
Carcinoma, Renal Cell
311
Adenocarcinoma of Lung
308
Squamous Cell Carcinoma of Head and Neck
304
Head and Neck Neoplasms
293
Prostatic Neoplasms
284
Mesothelioma, Malignant
281
Esophageal Neoplasms
265
Mesothelioma
244
Colonic Neoplasms
225
Brain Neoplasms
216
Urinary Bladder Neoplasms
212
Triple Negative Breast Neoplasms
209
Uterine Cervical Neoplasms
207
Endometrial Neoplasms
174
Sarcoma
171
Carcinoma, Hepatocellular
158
NSCLC
134
Kidney Neoplasms
127
Carcinoma
127
Interventions
regorafenib
1
brigimadlin
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Tertiary Lymphoid Structures
×
Thoracic
×
Clear all
NCT06084689
2025-09-02
EMPIRE
Institut Bergonié
Phase 2
Withdrawn
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled